Hideyuki Yoshitomi, Akira Togawa, Fumio Kimura, Hiroshi Ito, Hiroaki Shimizu, Hiroyuki Yoshidome, Masayuki Otsuka, Atsushi Kato, Satoshi Nozawa, Katsunori Furukawa, Masaru Miyazaki and Pancreatic Cancer Chemotherapy Program of the Chiba University Department of General Surgery Affiliated Hospital Group A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer Cancer 113
Version of Record online: 29 SEP 2008 | DOI: 10.1002/cncr.23863
The efficacy and feasibility of a gemcitabine (GEM) and uracil/tegafur (UFT) combination versus GEM alone was evaluated in patients with resected pancreatic cancer in a randomized phase II study. Although UFT did not show a survival benefit as adjuvant chemotherapy, adjuvant chemotherapy using GEM showed favorable results for resected pancreatic cancer.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field